替罗非班在非ST段抬高急性冠脉综合征介入治疗前后的研究

目的 探讨盐酸替罗非班对非ST段抬高急性冠脉综合征(NSTE-ACS)患者经皮冠状动脉介入治疗(PCI)的临床疗效和安全性.方法 将2009-07～2011-04间,植入药物洗脱支架(DES)NSTE-ACS患者随机分为替罗非班试验组(n=38)和对照组(n=36).比较PCI前后病变血管血流TIMI分级、出血事件和血...

Clinical Study of Pre-angiographic Use of Tirofiban in PCI for Non-ST Elevation Acute Coronary Syndrome

Objective To investigate the effect and safety of tirofiban in PCI patients with non-ST elevation acute coronary syndrome(NSTE-ACS).Methods From July 2009 to April 2011,74 high-risk patients with NSTE-ACS underwent drug-eluding stent(DES) implantation were divided into tirofiban group(n=38)and control group(n=36)randomly.Basic clinical characteristics,TIMI flow before and after PCI,incidences of bleeding and thrombocytopenia in the hospital,and the incidences of major cardiovascular events at 1 month were compared between two groups.Results The baseline clinical and angiographic characteristics,PCI procedures and immediate between the two groups had no significant difference.The percentage of TIMI 3 flow achieved in tirofiban group before PCI was higher than that in control group(71.1% VS 44.4%,P<0.05),but there were no significant difference in percentage of TIMI 3 flow achieved after PCI between the two groups.There were no significant differences in occurrence of bleeding complication and major cardiovascular events in both groups(P>0.05).Conclusion It is safe and effective for pre-angiographic use of tirofiban in PCI patients with NSTE-ACS.Tirofiban might increase blood flow before PCI,improve myocardial perfusion,and can not add bleeding complication.